GILEAD SCIENCES INC (GILD)
US3755581036 - Common Stock
Gilead Sciences to Present at Upcoming Investor Conference
Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold?
GILD has put up a steady performance in 2024, with a new drug approval, positive data readouts and strong quarterly results. We believe there is more room for growth, given GILD's strong fundamentals.
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?
Here is how Atossa Genetics Inc. (ATOS) and Gilead Sciences (GILD) have performed compared to their sector so far this year.
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future.
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
In the most recent trading session, Gilead Sciences (GILD) closed at $91.09, indicating a +0.44% shift from the previous trading day.
Is GILEAD SCIENCES INC Ready to Break Out of Its Range?
In-Depth Technical Analysis of GILEAD SCIENCES INC.
Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
GILD Obtains Positive CHMP Opinion for Liver Disease Drug
The CHMP recommends the approval of Gilead's seladelpar in combination with ursodeoxycholic acid for the treatment of primary biliary cholangitis in adults.
Gilead (GILD) Upgraded to Buy: Here's Why
Gilead (GILD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Gilead Sciences (GILD) Stock Moves -0.57%: What You Should Know
Gilead Sciences (GILD) concluded the recent trading session at $91.86, signifying a -0.57% move from its prior day's close.
Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis
Gilead appoints Sanofi official Dietmar Berger as next chief medical officer
Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent Merdad Parsey, who prepares to leave next year. Berger, who will join on Jan. 2, is French pharmaceutical giant Sanofi's current chief medical officer.
Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Unsupported price hikes added $815 million to US drug spending in 2023
Price increases for five of the 10 drugs that contributed the most to a rise in U.S. medical spending in 2023 were not supported by clinical evidence and drove costs higher by $815 million, an influential drug pricing watchdog said on Thursday. The Institute for Clinical and Economic Review (ICER) said that half of the drugs assessed had price increases based on new evidence of additional benefits or reduced harm, while the other half lacked such evidence. Johnson & Johnson's cancer drug Darzalex was on the list of price increases not backed by clinical evidence for the second time this year.
The Zacks Analyst Blog Highlights Eli Lilly, AbbVie, Gilead Sciences, Air T and Fossil Group
Eli Lilly, AbbVie, Gilead Sciences, Air T and Fossil Group are included in this Analyst Blog.
Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits
Top Stock Reports for Eli Lilly, AbbVie & Gilead Sciences
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie Inc. (ABBV) and Gilead Sciences, Inc. (GILD), as well as two micro-cap stocks, Air T, Inc. (AIRT) and Fossil Group, Inc. (FOSL).
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
The companies held competing events on Sunday to discuss their multiple myeloma treatments.
Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH
Gilead Collaborates With German Biotech Tubulis for Solid Tumor ADC
GILD and Germany-based Tubulis collaborate to discover and develop an antibody-drug conjugate against a solid tumor target.